<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335936">
  <stage>Registered</stage>
  <submitdate>7/09/2010</submitdate>
  <approvaldate>14/09/2010</approvaldate>
  <actrnumber>ACTRN12610000759099</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of Three Doses of Nebulized Epinephrine in Post-Extubation Croup</studytitle>
    <scientifictitle>In infants and children experiencing post-extubation stridor, is a 0.5, 2.5 or 5ml dose of Nebulized L-Epinephrine more effective in reducing stridor (Westley score)? A Prospective Randomized Double-Blind Study</scientifictitle>
    <utrn>U1111-1116-8338</utrn>
    <trialacronym />
    <secondaryid>not applicable</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>upper airway obstruction</healthcondition>
    <healthcondition>croup</healthcondition>
    <healthcondition>endotracheal intubation</healthcondition>
    <healthcondition>respiratory failure</healthcondition>
    <healthcondition>mechanical ventilation</healthcondition>
    <healthcondition>extubation failure</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention:nebulized l-epinephrine (1:1000)
Doses: 0.5 mL or 2.5 mL or 5 mL
Mode of administration: nebulization by face mask 
Duration: 15 minutes
Patients will be assigened  to one of three study treatments at 15 minutes post-extubation: 5 mL of l-adrenaline 1:1000 (group 1), 2.5 mL of l-adrenaline 1:1000 (group 2) or 0.5 mL of l-adrenaline 1:1000 (group 3). If the amount of l-epinephrine was less than 5 mL, isotonic saline was added until the volume achieved 5 mL. Research nurse will administer nebulizations over 15 minutes with a small, tight-fitting plastic face mask with an updraft nebulizer (Hudson RCI, Teleflex Medical, USA) connected to a source of pressurized oxygen with continuous flow of 100% oxygen at 5 L/min.  The nebulizers will be administered until empty.</interventions>
    <comparator>Dose comparison

Drug: l-epinephrine 1:1000 (1 mg)
Doses: 0.5 mL (0.5 mg) or 2.5 mL (2.5 mg) or 5 mL (5 mg)
Mode of administration: nebulization by face mask 
Duration: 15 minutes</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in the post-extubation stridor score (Westley score).  The Westley score evaluates five clinical parameters that are related to the degree of upper airway obstruction.  The scoring system ranges from 0 to 17 points, with 17 points indicating the most severe stridor.</outcome>
      <timepoint>Timepoints: at baseline (0 minute) and at 20, 40, 60, and 180 minutes after epinephrine nebulization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>respiratory rate (breaths per minute) will be continuously monitored by a multiparameter bedside monitor (DX 2020, Dixtal, Sao Paulo, Brazil)</outcome>
      <timepoint>at baseline (0 minute) and at 20, 40, 60, and 180 minutes after epinephine nebulization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>heart rate (beats per minute) will be continuously monitored by a multiparameter bedside monitor (DX 2020, Dixtal, Sao Paulo, Brazil)</outcome>
      <timepoint>at baseline (0 minute) and at 20, 40, 60, and 180 minutes after epinephrine nebulization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>non-invasive blood pressure (mmHg) will be monitored by a multiparameter monitor (DX 2020, Dixtal, Sao Paulo, Brazil)</outcome>
      <timepoint>at baseline (0 minute) and at 20, 40, 60, and 180 minutes after epinephrine nebulization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>oxygen saturation (%) on pulse oximetry will be continuously monitored by a bedside multiparameter monitor (DX 2020, Dixtal, Sao Paulo, Brazil)</outcome>
      <timepoint>at baseline (0 minute) and at 20, 40, 60, and 180 minutes after epinephrine nebulization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting hoarseness, a barking cough and inspiratory stridor after extubation and a Westley score more than 3.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous history of subglottic stenosis, laryngomalacia, infectious croup or use of corticosteroids within 48 hours prior to extubation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involved contacting the holder of the allocation schedule (study pharmacist) who was "off-site" (Department of Pharmacy) and had no contact with the study participants</concealment>
    <sequence>Permuted block randomisation by using a computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Paulo Sergio Lucas da Silva</primarysponsorname>
    <primarysponsoraddress>Pediatric Intensive Care Unit, Department of Pediatrics
Rua Castro Alves, 60 
Aclimacao, Sao Paulo
01532-900</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Hospital do Servidor Publico Municipal</fundingname>
      <fundingaddress>Rua Castro Alves, 60 
Aclimacao, Sao Paulo
01532-900</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Simone Brasil Oliveira Iglesias</othercollaboratorname>
      <othercollaboratoraddress>Estrada do Lutero, 1460 - Residencial Paisagem Renoir III - Granja Vianna - Cotia - Sao Paulo
 06715-400</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Although the use of nebulized epinephrine has been well studied and has a long history of use in children with viral croup, there is a few prospective studies investigating the effect of epinephrine on postextubation croup. However, there is no consensus in the literature regarding the appropriate dose of nebulized 1:1000 l-adrenaline that should be used to preventing postextubation croup.
The aim of this study is to compare the effectiveness and safety of nebulized l-epinephrine at dosage of 0.5 mL, 2.5 mL and 5 mL in the treatment of postextubation stridor</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee</ethicname>
      <ethicaddress>Rua Castro Alves, 60
Aclimacao, Sao Paulo 
01532-900</ethicaddress>
      <ethicapprovaldate>24/05/2010</ethicapprovaldate>
      <hrec>196/2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paulo Sergio Lucas da Silva</name>
      <address>Hospital do Servidor Publico Municipal, Pediatric Intensive Care Unit
Rua Castro Alves, 60, Aclimacao, Sao Paulo, Brazil 
01532-900</address>
      <phone>+551133972817</phone>
      <fax />
      <email>psls.nat@terra.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paulo Sergio Lucas da Silva</name>
      <address>Hospital do Servidor Publico Municipal, Pediatric Intensive Care Unit
Rua Castro Alves, 60, Aclimacao, Sao Paulo, Brazil 
01532-900</address>
      <phone>+551133972817</phone>
      <fax />
      <email>psls.nat@terra.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>